Marcinak, John F. http://orcid.org/0000-0002-9408-1889
Munsaka, Melvin S.
Watkins, Paul B.
Ohira, Takashi
Smith, Neila
Funding for this research was provided by:
Takeda Development Center Americas, Inc.
Article History
First Online: 28 February 2018
Change Date: 17 October 2018
Change Type: Correction
Change Details: In the original publication of the article, the ALT and AST values in Fig. 5a–e were capped at 10× ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig. 5a–e (Fig. 1a–e) and the correct Fig. 5a–5e (Fig. 2a–e) are published.
Compliance with ethical standards
:
: John F. Marcinak and Neila Smith are employed by Takeda Development Center Americas, Inc. (Deerfield, IL, USA). Melvin S. Munsaka is a former employee of Takeda Development Center Americas, Inc. Paul B. Watkins has served as a compensated consultant for Takeda regarding the liver safety of TAK-875 and other drugs. He received no compensation for the preparation of this article. Takashi Ohira is employed by Takeda Pharmaceutical Company Limited (Chuo-ku, Osaka, Japan).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.